Tonix in the News

Benzinga | Apr 27, 2023

A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US

STAT | Apr 20, 2023

The NIH has poured $1 billion into long Covid research — with little to show for it

BioSpace | Apr 13, 2023

Treatment Approach to Depression Sees Paradigm Shift

Inside Health Policy | Sep 29, 2022

Executive Order Could Lead To Big Subsidies For Domestic Biopharmaceutical Manufacturing

Nature Biotechnology | Sep 9, 2022

Monkeypox response relies on three vaccine suppliers

Endpoints News | Aug 24, 2022

'Nothing escapes our scientists': A handful of biotechs gear up work on monkeypox

The Frederick News-Post | Aug 18, 2022

Tonix Pharmaceuticals develops monkeypox vaccine for future by looking at past

BioProcess International | Aug 16, 2022

Tonix looks to live virus vaccines to prevent the spread of monkeypox

Proactive | Aug 11, 2022

Tonix Pharmaceuticals prepares to tackle monkeypox outbreak with TNX-801 vaccine

Benzinga | Jul 25, 2022

EXCLUSIVE: Tonix Pharmaceuticals CEO Highlights Advantages Of Company's Monkeypox Vaccine In Development

New Bedford Guide | Jun 22, 2022

Tonix Pharmaceuticals facility officially opens in the New Bedford Business Park

BioCentury | Jun 14, 2022

Poxvirus agents, by the mechanisms

The New York Times | Jun 3, 2022

21 Americans Infected With Monkeypox, C.D.C. Reports

Bioprocess Online | May 31, 2022

What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. (Podcast)

Proactive | May 25, 2022

Tonix Pharmaceuticals Talks Through its 1Q 2022 Financial and Operational Highlights

Benzinga | May 5, 2022

At Tonix, History Underpins a Modern Approach to COVID-19 Vaccines

Bloomberg | May 2, 2022

Balance of Power: Omicron Subvariant Raises Concerns (Podcast)

Benzinga | Apr 7, 2022

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

FiercePharma | Mar 8, 2022

Mass General plans study of nasally delivered binge eating disorder drug

Clinical Trials Arena | Feb 8, 2022

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Chronic Migraine and Major Depressive Disorder. Please visit Clinical Trials.

Tonix in the News

A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US

The NIH has poured $1 billion into long Covid research — with little to show for it

Treatment Approach to Depression Sees Paradigm Shift

Executive Order Could Lead To Big Subsidies For Domestic Biopharmaceutical Manufacturing

Monkeypox response relies on three vaccine suppliers

'Nothing escapes our scientists': A handful of biotechs gear up work on monkeypox

Tonix Pharmaceuticals develops monkeypox vaccine for future by looking at past

Tonix looks to live virus vaccines to prevent the spread of monkeypox

Tonix Pharmaceuticals prepares to tackle monkeypox outbreak with TNX-801 vaccine

EXCLUSIVE: Tonix Pharmaceuticals CEO Highlights Advantages Of Company's Monkeypox Vaccine In Development

Tonix Pharmaceuticals facility officially opens in the New Bedford Business Park

Poxvirus agents, by the mechanisms

21 Americans Infected With Monkeypox, C.D.C. Reports

What's Next For COVID Vaccines With Tonix Pharmaceuticals' Seth Lederman, M.D. (Podcast)

Tonix Pharmaceuticals Talks Through its 1Q 2022 Financial and Operational Highlights

At Tonix, History Underpins a Modern Approach to COVID-19 Vaccines

Balance of Power: Omicron Subvariant Raises Concerns (Podcast)

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Mass General plans study of nasally delivered binge eating disorder drug

Long Covid-19: Tonix reveals Phase II trial design plans